study of the effectiveness of "SALIRAVIRA" as a natural product on the treatment of COVID-19 patients

Study of the effectiveness of "SALIRAVIRA" as a natural product containing Licorice, Cone flower, Ginseng, Hyssop, Rhubarb and Rosemary extracts on the recovery of COVID-19 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201220049771N1

Enrollment

120

Registered

2020-12-31

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19 virus identified

Interventions

Intervention 1: Intervention group: Patients who receiving "SALIRAVIRA" containing mentioned extracts orally and respiratory spray at the same time in addition to standard treatments of COVID-19: 1- O

SALIRAVIRA tablet 750 mg

containing 500 mg of plant extracts mentioned before

4 times daily, Once every 6 hours (tablets are packed in blisters contain 10 tablet and will be provided to each case for the duration of treatment, ie 32 tablet) All process of extraction, production

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Clinical confirmation of coronavirus infection COVID-19 positive test reporting by RT-PCR Cases with contact history with a COVID-19 patients in last 10 days Lung involvement below 20% - Using CT-Scan

Exclusion criteria

Exclusion criteria: Pregnancy and Lactation cases Cases with malignant tumors and other acute systemic diseases or special indication Patients suffering from autoimmune diseases like Psoriasis, ALS and MS Patients with comorbidity of respiratory life-threatening problems Addiction to drugs and alcohol Participation to another clinical trial for COVID-19

Design outcomes

Primary

Measure	Time frame
Viral Clearance. Timepoint: At the beginning of the study and and 4, 8 days after intake. Method of measurement: Polymerase chain reaction (PCR).;Fever and symptoms. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Using a thermometer and clinical diagnosis.;Shortness of breath. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Medical diagnosis.	—

Measure

Time frame

Viral Clearance. Timepoint: At the beginning of the study and and 4, 8 days after intake. Method of measurement: Polymerase chain reaction (PCR).;Fever and symptoms. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Using a thermometer and clinical diagnosis.;Shortness of breath. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Medical diagnosis.

—

Secondary

Measure	Time frame
Olfactory (sense of smell). Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Questionnaire with interview.;Sense of taste. Timepoint: At the beginning of the study and daily during treatment after intake. Method of measurement: Questionnaire with interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaleh Ramezani Khorshiddoust

MimDaroo Pharmaceutical Co.

Saleh.rkh@gmail.com+98 21 9662 1410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026